- 著者
- Katsuo Usuda Aika Funazaki Ryo Maeda Atsushi Sekimura Nozomu Motono Munetaka Matoba Hidetaka Uramoto
- 出版者
- Annals of Thoracic and Cardiovascular Surgery 編集委員会
- 雑誌
- Annals of Thoracic and Cardiovascular Surgery (ISSN:13411098)
- 巻号頁・発行日
- pp.ra.17-00097, (Released:2017-10-04)
- 参考文献数
- 37
- 被引用文献数
- 13
This paper focuses on the latest research of diffusion-weighted magnetic resonance imaging (DWI), and deals with economic benefits, diagnostic benefits, and prospects of DWI for lung cancer. The medical cost of a magnetic resonance imaging (MRI) is 81%–84% cheaper than that of 18-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT). DWI is reported to be useful for differential diagnosis of malignancy or benignity for neoplasm in various organs. Diagnostic efficacy by DWI for pulmonary nodules and masses and the evaluation of N factor and M factor in lung cancer are equivalent to or more than that of FDG-PET/CT. The diagnostic capability of whole-body DWI (WB-DWI) for the staging of clinically operable lung cancers is equivalent to that of FDG-PET/CT and brain MRI, and WB-DWI is now becoming a more main stream procedure. Although the diagnostic performance of DWI for lung cancer may be equivalent to that of FDG-PET/CT, prospective randomized controlled trial for comparison of diagnostic efficacy between FDG-PET/CT and DWI for lung cancer is necessary for an accurate comparison. DWI may have an advantage in the aspect of the cost and diagnostic efficacy in lung cancer management.